119-HR-6089 Journalist Public Summary
119 · HR 6089 Biomanufacturing Excellence Act of 2025
Bipartisan bill to fund a National Biopharmaceutical Manufacturing Center of Excellence aimed at boosting U.S. drug manufacturing technology, workforce training, and supply-chain resilience; introduced Nov 18, 2025 and currently in the House Science Committee.
Headline Summary
A bipartisan House bill would fund a new National Biopharmaceutical Manufacturing Center of Excellence to speed drug production innovations, train workers, and reduce reliance on foreign supply chains.
What It Does
The bill creates a program at the National Institute of Standards and Technology (NIST) to award one competitive grant or agreement to an eligible non‑federal partner (such as a university or public‑private consortium) to stand up and run a National Biopharmaceutical Manufacturing Center of Excellence. The center would develop and demonstrate modern manufacturing technologies, improve production processes and equipment, support good manufacturing practices and standards, strengthen domestic supply chains, and expand workforce training through partnerships with schools, industry, and governments. It authorizes $120 million for fiscal year 2026 and directs NIST to solicit applications within 180 days of enactment, set intellectual‑property guidelines, and publish regular progress reports.
Who’s For It
- Lead sponsors: Reps. Chrissy Houlahan (D‑PA), Jim Baird (R‑IN), Deborah Ross (D‑NC), and David Rouzer (R‑NC) — signaling bipartisan support.
- Supporters’ case: Strengthens national, health, and economic security by bringing advanced drug manufacturing back home; helps small and large manufacturers scale new therapies; creates good‑paying jobs via targeted training; and coordinates standards that speed safe adoption of new methods.
Who’s Against It
- No named opponents yet at introduction.
- Potential concerns often raised about similar proposals: cost and whether funds will be appropriated each year; duplication with existing efforts (e.g., Manufacturing USA institutes or other federal R&D programs); government “picking winners”; and equitable access so benefits reach multiple regions, not just existing biotech hubs.
What’s Next
- Status as of November 19, 2025: Introduced on November 18, 2025 and referred to the House Committee on Science, Space, and Technology.
- Next steps: committee hearings/markup, a House floor vote, Senate consideration, and then the President. Authorization would still require annual appropriations to release funds.
Discussion